Is lithium indicated for reducing suicidality in adults with bipolar disorder or recurrent major depressive episodes?

Lithium for Suicidality

Lithium should be strongly considered for reducing suicide risk in adults with bipolar disorder and recurrent major depressive disorder, as it demonstrates the most robust evidence among all psychiatric medications for preventing completed suicide and suicide attempts.

Evidence for Anti-Suicidal Effects

The evidence supporting lithium's anti-suicidal properties is substantial and consistent across multiple study types:

In Bipolar Disorder

• Most recent high-quality evidence 1 demonstrates that adding lithium treatment reduces suicide attempts by 6.54-fold and suicidal ideation by 4.78-fold in bipolar disorder patients compared to treatment without lithium
• A 2025 meta-analysis 2 found lithium associated with reduced suicide attempts (OR = 0.73) and completed suicide (OR = 0.61), though statistical significance was limited by small sample sizes
• The 2023 CANMAT/ISBD guidelines 3 recognize lithium as a cornerstone treatment for bipolar disorder with established suicide prevention benefits

In Major Depressive Disorder

• The first meta-analysis specifically in recurrent MDD 4 showed lithium reduced overall suicide risk by 88.5% (0.17%/year vs 1.48%/year without lithium; IRR = 8.71, p = 0.0005)
• For completed suicides alone in MDD, lithium showed an 85% risk reduction (IRR = 6.77, p = 0.01) 4
• The 2025 study 1 confirmed similar protective effects in MDD patients as in bipolar disorder

Randomized Controlled Trial Evidence

A placebo-controlled RCT 5 in patients with recent suicide attempts showed that all completed suicides occurred in the placebo group (p = 0.049), though the overall difference in suicidal acts did not reach statistical significance due to sample size limitations.

Clinical Application Algorithm

For patients with bipolar disorder:

1. Lithium is FDA-approved for acute mania and maintenance therapy 6
2. Should be considered first-line for maintenance treatment, particularly when suicide risk is present 7
3. Requires settings with personnel and facilities for close clinical and laboratory monitoring 7

For patients with recurrent major depressive disorder:

1. Consider lithium as maintenance therapy when suicide risk is elevated
2. Evidence supports anti-suicidal effects comparable to those seen in bipolar disorder 4
3. Not FDA-approved specifically for MDD, but represents off-label use with strong evidence base

For acute suicidal crisis:

• The 2025 VA/DoD guidelines 8 note insufficient evidence to recommend for or against lithium for acute suicide risk reduction
• Lithium's anti-suicidal effects appear to manifest during maintenance treatment rather than acutely 9
• For acute settings, consider ketamine infusion for short-term suicidal ideation reduction in MDD 8

Important Caveats and Monitoring

Contraindications and Precautions

The FDA label 6 specifies lithium should generally not be given to patients with:

• Significant renal or cardiovascular disease
• Severe debilitation or dehydration
• Sodium depletion
• Concurrent diuretic use (very high toxicity risk)

Essential Monitoring Requirements

• Therapeutic lithium levels must be maintained (subtherapeutic levels in studies likely contributed to lack of statistical significance) 2
• Patients must maintain normal diet including salt and adequate fluid intake (2500-3000 mL) 6
• More frequent monitoring needed when combined with diuretics or ACE inhibitors 6
• NSAIDs can significantly increase lithium levels and require close monitoring 6

Treatment Fidelity Considerations

The magnitude of lithium's anti-suicidal effect depends heavily on:

• Achieving and maintaining therapeutic blood levels
• Treatment adherence over time
• Adequate duration of treatment (effects are preventive, not acute)

Mechanism and Timing

While the exact mechanisms remain uncertain 10, lithium likely produces:

• Direct anti-aggressive/anti-impulsive effects that contribute to anti-suicidal outcomes
• Indirect mood-stabilizing effects that reduce recurrence of depressive episodes when suicide risk peaks

The protective effects manifest during long-term maintenance treatment rather than in acute crisis situations 9. Studies show delays to suicidal outcomes with lithium treatment included 1.

Strength of Evidence

Lithium has the most abundant evidence of any psychiatric medication for reducing suicidal behavior 10. This includes:

• Multiple meta-analyses showing consistent effects 2, 4
• Long-term observational studies
• Randomized controlled trials (though limited by sample size)
• Evidence across both bipolar disorder and major depressive disorder

The failure to reach statistical significance in some analyses 2 likely represents type II error from small sample sizes rather than true lack of effect, as the direction and magnitude of benefit align consistently with larger observational studies.